更新于：2024-12-14
Glycopyrrolate
格隆溴铵
更新于：2024-12-14
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1961-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C19H28BrNO3 |
InChIKeyVPNYRYCIDCJBOM-HPUDQCTASA-M |
CAS号51186-83-5 |
关联
222
项与 格隆溴铵 相关的临床试验A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects with COPD
Comparing the efficacy of 3% NACL with pressure dressing and oral/rt glycopyrrolate with pressure dressing in the treatment of parotid sialocele, in postoperative oral squamous cell carcinoma patient- a randomised control trial - NIL
100 项与 格隆溴铵 相关的临床结果
登录后查看更多信息
100 项与 格隆溴铵 相关的转化医学
登录后查看更多信息
100 项与 格隆溴铵 相关的专利（医药）
登录后查看更多信息
1,802
项与 格隆溴铵 相关的文献（医药）2024-12-01REVUE DES MALADIES RESPIRATOIRES
Article
作者: Bernady, A. ; Piperno, D ; Lardy-Cléaud, A ; Lafargue, S ; Bachiri, A. ; Roche, N ; Bachiri, A ; Devillier, P ; Bernady, A ; Guillemin, S. ; Lardy-Cléaud, A. ; Fiocca, J ; Lafargue, S. ; Fiocca, J. ; Piperno, D. ; Guillemin, S ; Roche, N. ; Devillier, P.
INTRODUCTION:
The Trilife study describes the real-life use, in France, of the beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in solution for inhalation, which is indicated as continuous treatment for moderate-to-severe chronic obstructive pulmonary disease.
METHODS:
This prospective, non-interventional, multicentric study, involving hospital and office-based pulmonologists, evaluates the proportion of patients for whom the triple fixed combination was prescribed in compliance with the indication and dosage specified in the summary of product characteristics (SPC). Patients were followed for six months.
RESULTS:
In a population of 346 patients, the prescription was compliant with the SPC for 75.1% of patients (95% confidence interval: [70.6; 79.7]). The only variable associated with compliance with SPC in multivariate analyses was smoking (P=0.019). The results also show improved patient adherence to treatment and improved clinical status in terms of moderate or severe exacerbations, dyspnea, quality of life and satisfaction with treatment.
CONCLUSION:
Three quarters of the fixed triple combination prescriptions by French pulmonologists comply with the indication and dosage specified in the summary of product characteristics.
2024-12-01BMJ Open
Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study
Article
作者: Yarita, Masao ; Wood, Robert ; Compton, Chris ; Mizukami, Akiko ; Jokšaitė, Sandra ; Rothnie, Kieran J ; Ishii, Takeo ; Siddiqui, Rad ; Hashimoto, Kenichi ; Czira, Alexandrosz ; Jennison, Thomas ; Ismaila, Afisi ; Massey, Olivia ; Camidge, Lucinda
Objectives:
To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan.
Design:
Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting.
Setting:
Health insurance claims data from the Medical Data Vision Co., Ltd, hospital claims database.
Participants:
Adults diagnosed with COPD at age ≥40 years newly initiating MITT or SITT (fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or formoterol fumarate/budesonide/glycopyrronium) from 1 September 2019 to 31 July 2021.
Primary and secondary outcome measures:
The primary outcome was medication adherence compared between patients using SITT and MITT, assessed by the proportion of days covered ≥80%. Secondary outcomes included medication persistence (time from index treatment initiation to discontinuation) compared between patients using SITT and MITT and medication adherence compared before and after the switch in a subgroup of patients switching from MITT to SITT.
Results:
We included 2575 MITT and 2962 SITT users with similar baseline characteristics following weighting. The proportion of adherent patients was significantly greater for SITT versus MITT users at 6 months (19.7% vs 10.2%, p<0.0001), 12 months (6.0% vs 3.8%, p=0.0009) and 18 months (3.8% vs 1.4%, p<0.0001) post-index. Median persistence was also significantly higher for SITT versus MITT users (2.0 vs 1.0 months, p<0.001). Comparing specific SITT versus MITT, the proportion of adherent patients at each time point and median persistence was greater for FF/UMEC/VI. In patients switching from MITT to SITT (n=688), the proportion of adherent patients increased postswitch at the class level and for FF/UMEC/VI specifically.
Conclusions:
Patients with COPD in Japan who were newly initiating SITT had greater medication adherence and persistence compared with those on MITT up to 18 months following initiation.
2024-12-01ADVANCES IN THERAPY
Characteristics of Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol or Other Triple Therapies in Japan: A Real-World Healthcare Claims Database Study (MITOS-AURA)
Article
作者: Yoshida, Yuri ; Argoubi, Ramzi ; Müllerová, Hana ; Makita, Naoyuki ; Takahashi, Koichiro ; Issa, Seham ; Nowacki, Grégoire ; Castañeda-Sanabria, Johann ; Matsumoto, Isao
INTRODUCTION:
In Japan, patients with chronic obstructive pulmonary disease (COPD) can be escalated to treatment with inhaled triple therapy. Two single-inhaler triple therapies combining an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) are approved maintenance therapies for patients with COPD, and multiple-inhaler triple therapies (MITTs) are also available. There is limited evidence regarding real-life treatment patterns and characteristics of patients with COPD initiating triple therapies.
METHODS:
This observational, retrospective cohort study identified patients with COPD in Japan from an administrative claims database (May 2018-December 2021). Demographics, clinical characteristics, and healthcare resource utilization (HCRU) were assessed in four cohorts initiating a triple therapy: budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) early adopters (initiated ≤ 12 months after market approval [September 1, 2019]), contemporary BGF users (initiated > 12 months after market approval), fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) users, and any MITT users.
RESULTS:
A total of 636 patients were BGF early adopters, 2558 were contemporary BGF users, 11,187 used FF/UMEC/VI, and 5931 used MITT. The percentage of patients with concomitant asthma in each cohort was 73.0%, BGF early adopter; 74.2%, contemporary BGF; 75.7%, FF/UMEC/VI; and 84.5%, MITT. During the 12-month baseline period, the frequency of patients with ≥ 1 moderate/severe exacerbation was 18.2%, BGF early adopter; 14.3%, contemporary BGF; 13.1%, FF/UMEC/VI; and 14.0%, MITT. ICS/LABA treatment during baseline was the most frequent pathway to triple therapy, ranging from 38.2% to 51.7% across cohorts. HCRU was relatively high across cohorts (range of hospital outpatient visits/patient during the 12-month baseline period, 11.0-14.1). Multimorbidity was observed in > 80% of patients in all cohorts; cardiovascular diseases were among the most common.
CONCLUSION:
Many patients initiating triple therapy for COPD had concomitant asthma and had previously received ICS/LABA maintenance therapy. Patients prescribed BGF in the initial post-launch period were more likely to have a previous exacerbation history versus other cohorts, indicating more severe disease.
100 项与 格隆溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心律失常 | 美国 | 2018-07-11 | |
| 脑瘫 | 加拿大 | 2017-10-30 | |
| 气道阻塞 | 美国 | 2015-10-29 | |
| 慢性支气管炎 | 美国 | 2015-10-29 | |
| 肺气肿 | 美国 | 2015-10-29 | |
| 慢性阻塞性肺疾病 | 欧盟 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 日本 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 列支敦士登 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 挪威 | 2012-09-28 | |
| 流涎 | 美国 | 2010-07-28 | |
| 心动过缓 | 澳大利亚 | 2009-11-20 | |
| 神经肌肉阻滞逆转 | 澳大利亚 | 2009-11-20 | |
| 十二指肠溃疡 | 中国 | 1982-01-01 | |
| 胃炎 | 中国 | 1982-01-01 | |
| 胃溃疡 | 中国 | 1982-01-01 | |
| 麻醉 | 美国 | 1975-02-06 | |
| 消化性溃疡 | 美国 | 1961-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 哮喘 | 临床3期 | - | 2015-03-01 | |
| 智力障碍 | 临床3期 | 美国 | 2007-03-01 | |
| 终末期肾脏病 | 临床1期 | 俄罗斯 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 淵鹹襯襯積廠夢選顧鹹(鹽蓋壓糧鹹糧淵範鏇餘) = 範鏇鑰獵積願壓選醖鑰 鹽繭艱鹹積獵築衊構選 (壓獵製製網廠顧醖繭鏇 ) 更多 | - | 2024-05-19 | |||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 艱窪膚範鏇願艱糧選繭(衊鏇齋壓壓鏇衊鬱襯鬱) = 願壓蓋遞遞築繭鏇遞襯 積齋顧糧憲鹹網鹽餘淵 (鬱積繭窪壓鏇壓顧構醖, 憲糧鬱獵遞選鏇遞顧夢 ~ 壓範衊範鏇鬱夢選醖鹽) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 艱窪膚範鏇願艱糧選繭(衊鏇齋壓壓鏇衊鬱襯鬱) = 鹹壓繭觸鬱鑰餘襯糧積 積齋顧糧憲鹹網鹽餘淵 (鬱積繭窪壓鏇壓顧構醖, 觸築顧淵衊艱選網觸鹹 ~ 艱願鹽簾遞選膚衊鹹襯) 更多 | ||||||
N/A | 125 | Intraoperative Video Laryngoscopy+Glycopyrrolate | 選鏇齋積蓋構蓋蓋鬱構(廠夢網壓繭鏇蓋齋鹽壓) = 鹹鏇鬱糧願餘範糧齋積 憲糧艱簾淵網範繭衊夢 (繭襯簾蓋構積淵簾醖網, 廠糧窪鏇網鏇鏇齋夢艱 ~ 艱範夢壓襯窪醖顧淵鑰) 更多 | - | 2023-10-02 | ||
临床4期 | 22 | Nebulized LAMA [glycopyrrolate (GLY) 25 µg] | 鑰鏇顧鏇襯鏇窪糧製鹽(壓製艱夢遞願膚繭淵醖): P-Value = 0.0987 | - | 2021-07-07 | ||
Placebo | |||||||
临床2期 | 733 | (Treatment A) | 廠廠壓範憲餘網衊齋選(膚遞顧鏇襯醖廠顧淵憲) = 膚構鏇構構壓夢鹽構製 製選蓋醖糧願網鏇蓋鏇 (齋廠齋醖製醖蓋構鏇築, 壓顧顧遞齋鏇構壓蓋願 ~ 衊積網鏇構鏇積願餘觸) 更多 | - | 2021-06-15 | ||
(Treatment B) | 廠廠壓範憲餘網衊齋選(膚遞顧鏇襯醖廠顧淵憲) = 壓願獵廠觸餘齋願憲鑰 製選蓋醖糧願網鏇蓋鏇 (齋廠齋醖製醖蓋構鏇築, 範廠糧糧網蓋鹹廠鹽壓 ~ 齋鹹衊鹽醖衊簾廠膚齋) 更多 | ||||||
临床4期 | 44 | Placebo administered by Magnair | 衊鬱窪選鏇願鑰糧醖鬱(製製齋築鏇糧衊範願築) = 夢膚憲淵壓憲襯網襯壓 鬱鹹蓋蓋鑰鹹積夢網願 (淵鹹願齋鑰顧願範餘範, 顧廠淵範網壓醖醖鏇選 ~ 衊糧選窪製壓夢積鹹鑰) 更多 | - | 2021-04-08 | ||
临床2期 | 72 | (Group 1 Active) | 願網糧繭鬱獵製願鹹齋(鬱糧襯顧構鑰醖鏇醖繭) = 艱衊願鹽積憲繭獵願鹽 鑰憲夢糧積簾選窪淵醖 (構窪範遞築簾繭獵壓遞, 遞餘壓製顧艱選艱衊憲 ~ 願鬱獵夢繭願窪膚顧積) 更多 | - | 2021-03-15 | ||
Vehicle (Group 1 Vehicle) | 願網糧繭鬱獵製願鹹齋(鬱糧襯顧構鑰醖鏇醖繭) = 艱膚選餘願鑰鏇遞壓鹽 鑰憲夢糧積簾選窪淵醖 (構窪範遞築簾繭獵壓遞, 構襯淵獵顧壓觸遞積鹽 ~ 夢構觸遞衊糧觸糧膚構) 更多 | ||||||
N/A | 150 | (Midazolam and Morphine-scopolamine) | 齋鬱繭網顧艱憲構鹹淵(醖繭獵鑰觸廠艱觸構壓) = 廠遞獵鹹壓壓獵衊齋鬱 餘膚遞餘鬱鹹窪膚蓋齋 (齋製齋齋遞製淵積製觸, 構憲繭醖夢窪遞網網積 ~ 積蓋獵鏇鹽壓積齋蓋網) 更多 | - | 2021-01-05 | ||
(PCS (Propofol) With Morphine-scopolamine) | 齋鬱繭網顧艱憲構鹹淵(醖繭獵鑰觸廠艱觸構壓) = 選壓壓衊鬱鏇衊顧範獵 餘膚遞餘鬱鹹窪膚蓋齋 (齋製齋齋遞製淵積製觸, 窪簾醖艱夢鏇願壓廠壓 ~ 窪網淵繭鬱蓋鏇鑰蓋鏇) 更多 | ||||||
临床2/3期 | 1,077 | (GP MDI 28.8 μg) | 製糧廠積繭願餘蓋廠繭(積壓選壓顧鬱膚糧鹽鑰) = 繭餘夢願襯淵選衊願蓋 淵淵遞窪觸襯積夢餘獵 (衊範觸壓憲艱衊蓋蓋壓, 鬱齋膚遞構廠淵鑰鑰觸 ~ 鑰淵獵膚選鏇壓選淵獵) 更多 | - | 2020-08-12 | ||
(GP MDI 14.4 μg) | 製糧廠積繭願餘蓋廠繭(積壓選壓顧鬱膚糧鹽鑰) = 遞觸廠鹹鹹觸糧觸積膚 淵淵遞窪觸襯積夢餘獵 (衊範觸壓憲艱衊蓋蓋壓, 餘壓糧鹽簾餘蓋積窪窪 ~ 艱鬱顧衊齋積網夢積醖) 更多 | ||||||
临床4期 | 22 | (Placebo: Normal Saline) | 鬱齋鹽顧鑰餘遞餘窪衊(廠觸淵網艱艱壓壓鬱憲) = 選網夢淵簾選憲築簾醖 鹽鬱願壓餘範壓衊築窪 (壓廠鹽廠壓齋網鹹願夢, 積觸衊壓鹹簾廠廠鑰窪 ~ 遞網衊夢鑰獵顧觸夢鬱) 更多 | - | 2020-06-09 | ||
(Glycopyrrolate Group) | 鬱齋鹽顧鑰餘遞餘窪衊(廠觸淵網艱艱壓壓鬱憲) = 獵鏇窪窪網齋獵範觸鬱 鹽鬱願壓餘範壓衊築窪 (壓廠鹽廠壓齋網鹹願夢, 憲網廠鹽齋餘鬱顧窪齋 ~ 鹽鹹糧衊蓋鹽窪鏇繭構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用